{"id":41467,"date":"2026-08-27T01:55:15","date_gmt":"2026-08-27T01:55:15","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=41467"},"modified":"2026-08-27T02:34:23","modified_gmt":"2026-08-27T02:34:23","slug":"paradromics-receives-fda-approval-to-expand-bci-access-to-personal-computing-devices-in-clinical-study","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/de\/paradromics-receives-fda-approval-to-expand-bci-access-to-personal-computing-devices-in-clinical-study\/","title":{"rendered":"Paradromics Receives FDA Approval to Expand BCI Access to Personal Computing Devices in Clinical Study"},"content":{"rendered":"

Paradromics<\/a> has received an approval letter from the U.S. Food and Drug Administration (FDA) expanding the types of computing devices that may be used with its investigational brain-computer interface (BCI) system. The approval creates a pathway for Paradromics to support compatible personal, internet-connected devices through Convey, its user-facing system for translating decoded neural intent into communication and computer control. Following the agreed-upon deployment and testing process, compatible personal devices such as laptops, tablets, and phones can be added without requiring Paradromics to seek approval for each new device.<\/p>\n\n\n\n

The expansion represents a significant step beyond a company-provided computing environment and toward a BCI designed to work with the technology people use in their everyday lives. Convey is designed to serve as the connection between decoded neural intent and the digital world, processing brain signals to determine intended output and enabling that output to be used for communication and computer control across supported digital devices. The immediate value of the FDA expansion is greater flexibility and internet connectivity, but its longer-term significance is mobility. For future BCI users, personal computing could take many forms: a device mounted to a wheelchair, a laptop used for work, a tablet carried throughout the home, or a mobile device that travels with the user.<\/p>\n\n\n\n

Paradromics is initially evaluating its BCI platform for restoring communication and computer control in people with severe motor impairment. The FDA-approved Connect-One Early Feasibility Study is currently evaluating the Connexus Brain-Computer Interface, including its ability to safely restore communication and enable computer-device control. The expanded device pathway does not change the underlying clinical care model of the study; instead, it provides Paradromics with greater flexibility to evaluate how BCI-enabled computer control can eventually work within the personal digital environments of future users. The company’s broader development strategy is focused on creating a high-bandwidth neural interface capable of translating human intent into action across an expanding range of technologies and applications.<\/p>\n\n\n\n

Matt Angle, PhD, Founder and CEO of Paradromics, stated that as the company thinks about building BCI as a technology platform, it needs to push for generalized connectivity, meaning being able to connect with the products and technology that are already part of users’ lives. Angle noted that this approval begins clearing the way toward a BCI platform that can move with the user rather than tethering them to a fixed computing environment.<\/p>\n\n\n\n

William J. Marks Jr., MD, MS-HCM, Chief Clinical Officer of Paradromics, said we live much of our lives online, and access to a personal device can mean the ability to work, communicate with family, manage daily activities, and participate more fully in the world. Marks noted that designing for that experience is an important part of translating BCI technology from a clinical research system into something that can ultimately support people in everyday life.<\/p>","protected":false},"excerpt":{"rendered":"

Paradromics has received FDA approval to expand the types of computing devices that may be used with its investigational brain-computer interface (BCI) system in the Connect-One clinical study, enabling compatibility with personal laptops, tablets, and phones through its Convey user interface.<\/p>","protected":false},"author":2,"featured_media":41468,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[7,488,681,25],"tags":[802,687],"class_list":["post-41467","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-breaking-news","category-care-therapy","category-products-technologies","tag-bci","tag-fda"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts\/41467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/comments?post=41467"}],"version-history":[{"count":2,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts\/41467\/revisions"}],"predecessor-version":[{"id":41481,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts\/41467\/revisions\/41481"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/media\/41468"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/media?parent=41467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/categories?post=41467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/tags?post=41467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}